Endocrine Abstracts

Background: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In vitro, sirolimus inhibits differentiation of orbital fibroblasts from patients with Graves’ orbitopathy (GO), suggesting a possible use in clinical practice.Methods: We performed a retrospective investigation aimed at evaluating the effects of sirolimus as a second-line treatment for moderate-to-severe, active GO, compared with methyl...

Objectives: Optimal treatment for Graves’ hyperthyroidism (GH) in patients with moderate-to-severe, active Graves’ orbitopathy (GO) remains to be established. There is debate on whether a conservative (antithyroid drugs, ATDs) or an ablative approach (radioactive iodine, RAI, or surgery, Tx)has to be preferred. The aim of the present study was to investigate whether these different approachesresult in a different outcome of GOfollowing intravenous glucocorticoids (iv...

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In a recent study, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 6 months compared to the standard treatment (intravenous glucocorticoids). Here we investigated the effects of sirolimus over a longer period of time.Methods: The study design entailed data anal...

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti- proliferative activities. Recently, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 24 weeks compared to methylprednisolone. Here we conducted a retrospective study to investigate the efficacy and safety of sirolimus compared with methylprednisolone over a longer period of time.Methods...